Roche gets FDA approval for Vabysmo to treat nAMD and DME
Vabysmo inhibits disease pathways that drive neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
01 Feb 22
Vabysmo inhibits disease pathways that drive neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)
01 Feb 22
Spikevax is the second Covid-19 vaccine to get full approval in the US, following Pfizer and BioNTech’s Covid-19…
31 Jan 22
We focus on the challenges facing those running clinical trials and how technology could be used to help…
31 Jan 22
The new facility will use advanced technology to produce parenteral products and devices and expand Lilly’s manufacturing capacity
31 Jan 22
The EC approval was based on results from the Phase 3 CROWN trial, in which Lorviqua reduced the…
28 Jan 22
Samsung Biologics said that the transaction would advance Samsung Bioepis’ capabilities in biosimilar development and future performance in…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
28 Jan 22
The positive CHMP recommendation was based on evidence supporting Paxlovid, including data from the Phase 2/3 EPIC-HR trial
27 Jan 22
The 90,000ft² manufacturing facility, Atara T-cell Operations and Manufacturing (ATOM), supports clinical and commercial cell therapy manufacturing and…
25 Jan 22
The US agency revised the EUAs for Lilly’s bamlanivimab plus etesevimab regimen, and Regeneron’s REGEN-COV, based on the…
25 Jan 22
Gefapixant is a non-narcotic selective P2X3 receptor antagonist intended for the treatment of refractory (RCC) or unexplained chronic…